<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734370</url>
  </required_header>
  <id_info>
    <org_study_id>KP-2008-518</org_study_id>
    <nct_id>NCT00734370</nct_id>
  </id_info>
  <brief_title>Virtual Reality Exposure Therapy in Agoraphobic Participants</brief_title>
  <official_title>Virtual Reality Exposure Therapy in Agoraphobic Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University of Amsterdam</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Virtual Reality Exposure Therapy (VRET) is an effective treatment for anxiety disorders,
      particularly for specific phobias as fear of heights and fear of flying (e.g. Powers &amp;
      Emmelkamp, 2008). Recent technological advances (e.g. more realistic avatars) make research
      into the efficacy of VRET for participants with elevated agoraphobic symptoms desirable.
      Therefore, the aim of the present research proposal is to investigate the comparative
      efficacy of:

        1. enhanced VRET making use of the latest avatar technology with

        2. exposure in vivo in agoraphobic participants

        3. wait-list control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Panic Disorder Severity Scale (PDSS); Mobility Inventory for Agoraphobia (MI); Behavioural Avoidance Test (BAT)</measure>
    <time_frame>Assessed at pre- and post-treatment and 6-12 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI); Anxiety Sensitivity Inventory (ASI); Beck Depression Inventory (BDI); Panic Disorder Severity Scale (PDSS); Agoraphobic Cognitions Questionnaire (ACQ); Bodily Sensations Questionnaire (BSQ); Panic Appraisal Inventory (PAI)</measure>
    <time_frame>Process measures: are taken prior to treatment, after the fourth treatment session and at post-treatment. The PDSS and PAI will be administered every therapy session</time_frame>
    <description>Process measures are taken prior to treatment, after the fourth treatment session and at post-treatment. The same measures will also be taken at 6 months follow-up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Panic Disorder</condition>
  <condition>Agoraphobia</condition>
  <arm_group>
    <arm_group_label>VRET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual Reality Exposure Therapy for agoraphobic participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exposure in vivo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard exposure in vivo for panic disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-list control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual Reality Exposure Therapy for agoraphobic participants</intervention_name>
    <description>This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
Psycho-education, breathing training and cognitive restructuring
Virtual reality Exposure to agoraphobic situations and interoceptive exposure
Relapse prevention</description>
    <arm_group_label>VRET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard exposure in vivo for agoraphobic participants</intervention_name>
    <description>This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
Psycho-education, breathing training and cognitive restructuring
Standard exposure in vivo to agoraphobic situations and interoceptive exposure
Relapse prevention (according to the protocol of Craske &amp; Barlow)</description>
    <arm_group_label>Exposure in vivo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A full diagnosis of panic disorder with agoraphobia according to the DSM-IV

          -  Between the ages of 18-65 years

          -  Sufficient fluency in Dutch to complete treatment and research protocol

        Exclusion Criteria:

          -  Presence of medical condition, assessed by self-report questionnaires at the intake
             (i.e., pregnancy, seizure disorder, pacemaker)

          -  Current use of Beta-blockers

          -  Current use of tranquilizers (Benzodiazepines)

          -  Unstable psychotropic medication

          -  Substance dependence

          -  Psychosis

          -  Depression with suicidal ideation

          -  Posttraumatic Stress Disorder

          -  Dementia or other severe cognitive impairment

          -  Bipolar Disorder

          -  Borderline Personality Disorder

          -  Anti-social Personality Disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul MG Emmelkamp, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University of Amsterdam</investigator_affiliation>
    <investigator_full_name>Paul M.G.Emmelkamp</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Panic Disorder and Agoraphobia</keyword>
  <keyword>Virtual Reality Exposure Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panic Disorder</mesh_term>
    <mesh_term>Agoraphobia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

